Marshall Wace North America L.P. Buys Shares of 16,938 ChemoCentryx Inc (NASDAQ:CCXI)

Marshall Wace North America L.P. bought a new stake in ChemoCentryx Inc (NASDAQ:CCXI) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 16,938 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

Other large investors have also recently modified their holdings of the company. Rhumbline Advisers increased its stake in ChemoCentryx by 44.9% in the fourth quarter. Rhumbline Advisers now owns 30,596 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 9,479 shares in the last quarter. SG Americas Securities LLC bought a new stake in ChemoCentryx in the fourth quarter valued at approximately $196,000. Raymond James & Associates bought a new stake in ChemoCentryx in the fourth quarter valued at approximately $133,000. Dimensional Fund Advisors LP increased its stake in ChemoCentryx by 15.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 632,061 shares of the biopharmaceutical company’s stock valued at $6,896,000 after purchasing an additional 84,290 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in ChemoCentryx by 10.2% in the fourth quarter. Bank of New York Mellon Corp now owns 139,805 shares of the biopharmaceutical company’s stock valued at $1,525,000 after purchasing an additional 12,957 shares in the last quarter. 58.12% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Geoffrey M. Parker sold 12,815 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $12.00, for a total transaction of $153,780.00. Following the completion of the transaction, the director now owns 85,014 shares in the company, valued at $1,020,168. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 12.20% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. HC Wainwright increased their price objective on shares of Applied Genetic Technologies from $5.75 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. BidaskClub downgraded shares of Virtu Financial from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 12th. Zacks Investment Research raised shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Finally, Canaccord Genuity reissued a “buy” rating and set a GBX 285 ($3.72) price objective on shares of in a research report on Thursday, June 6th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. ChemoCentryx presently has an average rating of “Buy” and a consensus price target of $17.71.

CCXI traded down $0.12 during trading hours on Friday, hitting $8.16. 264,994 shares of the company’s stock were exchanged, compared to its average volume of 579,603. ChemoCentryx Inc has a 1-year low of $7.93 and a 1-year high of $14.98. The firm has a 50-day moving average price of $8.93. The company has a market capitalization of $480.64 million, a PE ratio of -10.74 and a beta of 1.11. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.43 and a current ratio of 3.43.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. ChemoCentryx had a negative net margin of 97.22% and a negative return on equity of 111.15%. The business had revenue of $8.33 million during the quarter, compared to analysts’ expectations of $11.37 million. As a group, sell-side analysts anticipate that ChemoCentryx Inc will post -0.92 EPS for the current fiscal year.

About ChemoCentryx

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

See Also: What is the Stochastic Momentum Index (SMI)?

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.